Serum Institute of India seeks DCGI permission for phase 2/3 clinical trials of Oxford#39;s COVID #39;vaccine#39;

Serum Institute of India seeks DCGI permission for phase 2/3 clinical trials of Oxford#39;s COVID #39;vaccine#39; The sources told PTI that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials of #39;Covidshield#39;.

No comments:

Post a Comment